GLP-1 Drugs Show 42 Percent Lower Risk of Worsening Mental Health, New Research Finds
A new study found that people taking GLP-1 medications like Ozempic and Wegovy had a 42 percent lower risk of worsening anxiety and depression compared to those not on the drugs. The findings add to growing evidence that GLP-1s may have benefits beyond weight loss.
GLP-1 medications, already known for their effects on weight and blood sugar, may also protect against worsening mental health conditions, according to new research published this month.
The study found that people taking GLP-1 drugs like semaglutide, sold under the brand names Ozempic and Wegovy, had a 42 percent lower risk of worsening anxiety and depression compared to people not taking the medications. Researchers said the finding was unexpected and warrants further investigation.
GLP-1 drugs work by mimicking a hormone that regulates blood sugar and appetite. They were originally developed for type 2 diabetes and later approved for weight loss. The mental health finding suggests the drugs may also affect brain chemistry in ways that researchers do not yet fully understand.
The study adds to a complicated picture of GLP-1 side effects and benefits. Earlier research raised concerns that the drugs might increase the risk of suicidal thoughts in some patients, though regulators later said the evidence did not support a causal link. The new study points in the opposite direction, suggesting the drugs may actually improve mental health outcomes for many users.
Separately, the FDA approved a higher-dose version of Wegovy this month, which clinical trials showed produces greater weight loss than the standard dose. The agency also cleared Foundayo, the first once-daily oral GLP-1 pill, which is now available through Amazon One Medical kiosks.
Research published alongside the mental health study found that the effectiveness of GLP-1 drugs varies by genetics. About 10 percent of people have genetic variations that make the drugs less effective for them, which could explain why some patients see little benefit.
Doctors say the new mental health data is promising but should not change prescribing practices until larger, more controlled studies confirm the findings. They also caution that GLP-1 drugs can cause significant side effects, including nausea, vomiting, and muscle loss, and are not appropriate for everyone.
